440 related articles for article (PubMed ID: 32528470)
21. Host response to immune checkpoint inhibitors contributes to tumor aggressiveness.
Khononov I; Jacob E; Fremder E; Dahan N; Harel M; Raviv Z; Krastev B; Shaked Y
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33707313
[TBL] [Abstract][Full Text] [Related]
22. Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways.
Cecil D; Park KH; Curtis B; Corulli L; Disis MN
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762321
[TBL] [Abstract][Full Text] [Related]
23. Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade.
Li T; Hua C; Yue W; Wu J; Lv X; Wei Q; Zhu S; Zang G; Cui J; Liu YJ; Chen J
Pharmacol Res; 2020 Nov; 161():105293. PubMed ID: 33176206
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic efficacy of PD1/PDL1 blockade in B16 melanoma is greatly enhanced by immunization with dendritic cell-targeting lentiviral vector and protein vaccine.
Albershardt TC; Parsons AJ; Reeves RS; Flynn PA; Campbell DJ; Ter Meulen J; Berglund P
Vaccine; 2020 Apr; 38(17):3369-3377. PubMed ID: 32088020
[TBL] [Abstract][Full Text] [Related]
25. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design.
Yip YL; Smith G; Koch J; Dübel S; Ward RL
J Immunol; 2001 Apr; 166(8):5271-8. PubMed ID: 11290813
[TBL] [Abstract][Full Text] [Related]
26. Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide.
Tobias J; Jasinska J; Baier K; Kundi M; Ede N; Zielinski C; Wiedermann U
BMC Cancer; 2017 Feb; 17(1):118. PubMed ID: 28183282
[TBL] [Abstract][Full Text] [Related]
27.
Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
[TBL] [Abstract][Full Text] [Related]
28. Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity.
Sun L; Li CW; Chung EM; Yang R; Kim YS; Park AH; Lai YJ; Yang Y; Wang YH; Liu J; Qiu Y; Khoo KH; Yao J; Hsu JL; Cha JH; Chan LC; Hsu JM; Lee HH; Yoo SS; Hung MC
Cancer Res; 2020 Jun; 80(11):2298-2310. PubMed ID: 32156778
[TBL] [Abstract][Full Text] [Related]
29. Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants.
Saleh R; Toor SM; Al-Ali D; Sasidharan Nair V; Elkord E
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32616706
[TBL] [Abstract][Full Text] [Related]
30. Antitumor effect of new HER2 peptide vaccination based on B cell epitope.
Miyako H; Kametani Y; Katano I; Ito R; Tsuda B; Furukawa A; Saito Y; Ishikawa D; Ogino K; Sasaki S; Imai K; Habu S; Makuuchi H; Tokuda Y
Anticancer Res; 2011 Oct; 31(10):3361-8. PubMed ID: 21965747
[TBL] [Abstract][Full Text] [Related]
31. Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target.
Pierini S; Tanyi JL; Simpkins F; George E; Uribe-Herranz M; Drapkin R; Burger R; Morgan MA; Facciabene A
JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32814714
[TBL] [Abstract][Full Text] [Related]
32. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious Disease Vaccines and Therapeutics.
Kotraiah V; Phares TW; Browne CD; Pannucci J; Mansour M; Noe AR; Tucker KD; Christen JM; Reed C; MacKay A; Weir GM; Rajagopalan R; Stanford MM; Chung CS; Ayala A; Huang J; Tsuji M; Gutierrez GM
Front Immunol; 2020; 11():264. PubMed ID: 32210956
[TBL] [Abstract][Full Text] [Related]
33. Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer.
Tobias J; Drinić M; Schmid A; Hladik A; Watzenböck ML; Battin C; Garner-Spitzer E; Steinberger P; Kundi M; Knapp S; Zielinski CC; Wiedermann U
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428769
[TBL] [Abstract][Full Text] [Related]
34. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
[TBL] [Abstract][Full Text] [Related]
35. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.
Rekoske BT; Smith HA; Olson BM; Maricque BB; McNeel DG
Cancer Immunol Res; 2015 Aug; 3(8):946-55. PubMed ID: 26041735
[TBL] [Abstract][Full Text] [Related]
36. Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform.
Gjetting T; Gad M; Fröhlich C; Lindsted T; Melander MC; Bhatia VK; Grandal MM; Dietrich N; Uhlenbrock F; Galler GR; Strandh M; Lantto J; Bouquin T; Horak ID; Kragh M; Pedersen MW; Koefoed K
MAbs; 2019; 11(4):666-680. PubMed ID: 31046547
[TBL] [Abstract][Full Text] [Related]
37. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
38. Generation of Her-2/neu vaccine utilizing idiotypic network cascade.
Pal S; Saha A; Mohanty K; Mallick P; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
Cancer Biol Ther; 2007 Dec; 6(12):1916-25. PubMed ID: 18059165
[TBL] [Abstract][Full Text] [Related]
39. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
40. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
